US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
US4978672A
(en)
|
1986-03-07 |
1990-12-18 |
Ciba-Geigy Corporation |
Alpha-heterocyclc substituted tolunitriles
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
ATE95193T1
(de)
|
1987-06-17 |
1993-10-15 |
Sandoz Ag |
Cyclosporine und deren benutzung als arzneimittel.
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
DE68927933T2
(de)
|
1988-09-02 |
1997-08-14 |
Dyax Corp |
Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
GB8905669D0
(en)
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
SG48759A1
(en)
|
1990-01-12 |
2002-07-23 |
Abgenix Inc |
Generation of xenogenic antibodies
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
ATE185601T1
(de)
|
1990-07-10 |
1999-10-15 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
WO1992003917A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International |
Homologous recombination in mammalian cells
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
EP0575485A1
(en)
|
1991-03-01 |
1993-12-29 |
Dyax Corp. |
Process for the development of binding mini-proteins
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
WO1992018619A1
(en)
|
1991-04-10 |
1992-10-29 |
The Scripps Research Institute |
Heterodimeric receptor libraries using phagemids
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
CA2128511C
(en)
|
1992-01-23 |
2006-11-07 |
Andreas Pluckthun |
Monomeric and dimeric antibody-fragment fusion proteins
|
DE69334255D1
(de)
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
CA2076465C
(en)
|
1992-03-25 |
2002-11-26 |
Ravi V. J. Chari |
Cell binding agent conjugates of analogues and derivatives of cc-1065
|
CA2135408A1
(en)
|
1992-05-08 |
1993-11-25 |
Peter C. Keck |
Chimeric multivalent protein analogues and methods of use thereof
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
DK1087013T3
(da)
|
1992-08-21 |
2009-05-11 |
Univ Bruxelles |
Immunoglobuliner uden lette kæder
|
WO1994007921A1
(en)
|
1992-09-25 |
1994-04-14 |
Commonwealth Scientific And Industrial Research Organisation |
Target binding polypeptide
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
DE69232539T3
(de)
|
1992-10-28 |
2007-01-04 |
Genentech, Inc., South San Francisco |
Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
|
US5837821A
(en)
|
1992-11-04 |
1998-11-17 |
City Of Hope |
Antibody construct
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
US5837242A
(en)
|
1992-12-04 |
1998-11-17 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
WO1996013583A2
(en)
|
1994-10-20 |
1996-05-09 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Targeted hetero-association of recombinant proteins to multi-functional complexes
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
EP0827544B1
(en)
|
1995-05-23 |
2004-08-18 |
MorphoSys AG |
Multimeric proteins
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
CN1173878A
(zh)
|
1995-10-16 |
1998-02-18 |
尤尼利弗公司 |
双功能或双价抗体片段类似物
|
WO1997038102A1
(en)
|
1996-04-04 |
1997-10-16 |
Unilever Plc |
Multivalent and multispecific antigen-binding protein
|
TW533205B
(en)
|
1996-06-25 |
2003-05-21 |
Novartis Ag |
Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
|
DE69738749D1
(de)
|
1996-08-16 |
2008-07-17 |
Schering Corp |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
SI1325932T1
(pt)
|
1997-04-07 |
2005-08-31 |
Genentech Inc |
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
DE69841815D1
(de)
|
1997-04-07 |
2010-09-16 |
Genentech Inc |
Anti-VEGF Antikörper
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
US6323322B1
(en)
|
1997-04-30 |
2001-11-27 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
PT1012280E
(pt)
|
1997-06-11 |
2005-02-28 |
Borean Pharma As |
Modulo de trimerizacao
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
EP1025228A4
(en)
|
1997-10-21 |
2002-09-18 |
Human Genome Sciences Inc |
HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
|
WO1999023221A2
(en)
|
1997-10-27 |
1999-05-14 |
Unilever Plc |
Multivalent antigen-binding proteins
|
WO1999037791A1
(en)
|
1998-01-23 |
1999-07-29 |
Vlaams Interuniversitair Instituut Voor Biotechnologie |
Multipurpose antibody derivatives
|
AU2591599A
(en)
|
1998-02-09 |
1999-08-23 |
Genentech Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
ES2246567T3
(es)
|
1998-04-15 |
2006-02-16 |
Brigham & Womens Hospital |
Composiciones para receptores inhibidores de celulas t y usos de las mismas.
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
DK1100830T3
(da)
|
1998-07-28 |
2004-01-19 |
Micromet Ag |
Heterominiantistoffer
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
PT1196186E
(pt)
|
1999-07-12 |
2008-02-14 |
Genentech Inc |
Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
DK2857516T3
(en)
|
2000-04-11 |
2017-08-07 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
US20020103345A1
(en)
|
2000-05-24 |
2002-08-01 |
Zhenping Zhu |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
WO2002002781A1
(en)
|
2000-06-30 |
2002-01-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
CN1461344A
(zh)
|
2000-07-25 |
2003-12-10 |
免疫医疗公司 |
多价靶结合蛋白
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
US20040242847A1
(en)
|
2000-10-20 |
2004-12-02 |
Naoshi Fukushima |
Degraded agonist antibody
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
AU2002247826A1
(en)
|
2001-03-13 |
2002-09-24 |
University College London |
Specific binding members
|
DK1399484T3
(da)
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
DE60124912T2
(de)
|
2001-09-14 |
2007-06-14 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, Tandem-Fv-Antikörper
|
TWI302836B
(en)
|
2001-10-30 |
2008-11-11 |
Novartis Ag |
Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
|
US20030211078A1
(en)
|
2001-12-07 |
2003-11-13 |
Heavner George A. |
Pseudo-antibody constructs
|
KR101004224B1
(ko)
|
2002-02-01 |
2010-12-27 |
어리어드 파마슈티칼스, 인코포레이티드 |
인 함유 화합물 및 이의 용도
|
EP1487879B1
(en)
|
2002-03-01 |
2012-12-26 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
HUE025767T2
(en)
|
2002-03-13 |
2016-05-30 |
Array Biopharma Inc |
N3-alkylated benzimidazole derivatives as MEK inhibitors
|
JP4386741B2
(ja)
|
2002-04-15 |
2009-12-16 |
中外製薬株式会社 |
scDbライブラリーの作成方法
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
WO2004045532A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
CN1771235B
(zh)
|
2003-02-11 |
2010-04-28 |
弗奈利斯(剑桥)有限公司 |
异噁唑化合物
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
EP1618181B1
(en)
|
2003-04-22 |
2014-10-15 |
IBC Pharmaceuticals |
Polyvalent protein complex
|
AU2004244626A1
(en)
|
2003-05-23 |
2004-12-09 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
KR20060006975A
(ko)
|
2003-05-30 |
2006-01-20 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
WO2005000898A2
(en)
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
AU2004255216B2
(en)
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005035586A1
(ja)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
融合蛋白質組成物
|
JP2007509185A
(ja)
|
2003-10-27 |
2007-04-12 |
ノバルティス アクチエンゲゼルシャフト |
βアミロイド産生および/または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
|
WO2005055808A2
(en)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions and methods to diagnose and treat lung cancer
|
US20050136051A1
(en)
|
2003-12-22 |
2005-06-23 |
Bernard Scallon |
Methods for generating multimeric molecules
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
HUE026132T2
(en)
|
2004-01-07 |
2016-05-30 |
Novartis Vaccines & Diagnostics Inc |
M-CSF-specific monoclonal antibody and its uses
|
EP1711495A2
(en)
|
2004-01-23 |
2006-10-18 |
Amgen Inc. |
Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
EP1761540B1
(en)
|
2004-05-13 |
2016-09-28 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
CN101006086B
(zh)
|
2004-06-11 |
2010-09-29 |
日本烟草产业株式会社 |
用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
EP1786918A4
(en)
|
2004-07-17 |
2009-02-11 |
Imclone Systems Inc |
NEW BISPECIFIC ANTIBODY TETRAVALENT
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
JP2008511337A
(ja)
|
2004-09-02 |
2008-04-17 |
ジェネンテック・インコーポレーテッド |
ヘテロ多量体分子
|
CA2597098C
(en)
|
2005-02-08 |
2016-08-02 |
Steven R. Ledbetter |
Antibodies to tgfbeta
|
EP2343320B1
(en)
|
2005-03-25 |
2017-10-25 |
GITR, Inc. |
Anti-gitr antibodies and uses thereof
|
ES2592271T3
(es)
|
2005-03-31 |
2016-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
|
JP5011277B2
(ja)
|
2005-04-06 |
2012-08-29 |
アイビーシー・ファーマシューティカルズ・インコーポレーテッド |
ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
|
WO2006113665A2
(en)
|
2005-04-15 |
2006-10-26 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
ES2605380T3
(es)
|
2005-05-06 |
2017-03-14 |
Providence Health & Services - Oregon |
Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
|
ES2427646T5
(es)
|
2005-05-09 |
2017-08-22 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
WO2007004415A1
(ja)
|
2005-07-01 |
2007-01-11 |
Murata Manufacturing Co., Ltd. |
多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
DE602005018477D1
(de)
|
2005-08-26 |
2010-02-04 |
Pls Design Gmbh |
Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen
|
PE20070427A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
WO2007062466A1
(en)
|
2005-11-29 |
2007-06-07 |
The University Of Sydney |
Demibodies: dimerisation-activated therapeutic agents
|
US9387242B2
(en)
|
2005-12-02 |
2016-07-12 |
Icahn School Of Medicine At Mount Sinai |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
PL2347775T3
(pl)
|
2005-12-13 |
2020-11-16 |
President And Fellows Of Harvard College |
Rusztowania do przeszczepiania komórek
|
WO2007070750A1
(en)
|
2005-12-13 |
2007-06-21 |
Eli Lilly And Company |
Anti-il-17 antibodies
|
ES2611588T3
(es)
|
2005-12-13 |
2017-05-09 |
Incyte Holdings Corporation |
Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
|
WO2007133822A1
(en)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Gitr antibodies for the treatment of cancer
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
AU2007215013A1
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Functional antibodies
|
JP5374359B2
(ja)
|
2006-03-17 |
2013-12-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
安定化されたポリペプチド化合物
|
US8946391B2
(en)
|
2006-03-24 |
2015-02-03 |
The Regents Of The University Of California |
Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
|
AR060070A1
(es)
|
2006-03-24 |
2008-05-21 |
Merck Patent Gmbh |
Dominios proteicos heterodimericos obtenidos por ingenieria
|
EP4218801A3
(en)
|
2006-03-31 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
EP2010528B1
(en)
|
2006-04-19 |
2017-10-04 |
Novartis AG |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
EP2799449A1
(en)
|
2006-05-25 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Dimeric molecular complexes
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
CA3149553C
(en)
|
2006-06-12 |
2023-11-21 |
Aptevo Research And Development Llc |
Single-chain multivalent binding proteins with effector function
|
PE20110220A1
(es)
|
2006-08-02 |
2011-04-11 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
ME00588A
(en)
|
2006-08-18 |
2011-12-20 |
|
Prlr-specific antibody and uses thereof
|
US8759297B2
(en)
|
2006-08-18 |
2014-06-24 |
Armagen Technologies, Inc. |
Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
|
AU2007286808B2
(en)
|
2006-08-21 |
2012-12-06 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
EP2078040B1
(en)
|
2006-11-02 |
2017-06-28 |
Daniel J. Capon |
Methods of producing hybrid polypeptides with moving parts
|
ME02372B
(me)
|
2006-11-22 |
2016-06-20 |
Incyte Holdings Corp |
Imidazotriazini i imidazopiramidini kao inhibitori kinaze
|
US20080318886A1
(en)
|
2006-12-05 |
2008-12-25 |
Prussak Charles E |
Methods of Increasing Cancer Sensitivity to Chemotherapeutic Agents Using Chimeric ISF35
|
PL2091918T3
(pl)
|
2006-12-08 |
2015-02-27 |
Novartis Ag |
Związki i kompozycje jako inhibitory kinazy białkowej
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
US20080260738A1
(en)
|
2007-04-18 |
2008-10-23 |
Moore Margaret D |
Single chain fc, methods of making and methods of treatment
|
RS53072B
(en)
|
2007-06-18 |
2014-04-30 |
Merck Sharp & Dohme B.V. |
HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
|
WO2009002401A2
(en)
|
2007-06-21 |
2008-12-31 |
President And Fellows Of Harvard College |
Scaffolds for cell collection or elimination
|
JP2010531878A
(ja)
|
2007-06-27 |
2010-09-30 |
マリン ポリマー テクノロジーズ,インコーポレーテッド |
IL‐15とIL‐15Rαとの複合体及びその使用
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
US9624309B2
(en)
|
2007-08-15 |
2017-04-18 |
Bayer Intellectual Property Gmbh |
Monospecific and multispecific antibodies and method of use
|
US20110189203A1
(en)
|
2007-11-27 |
2011-08-04 |
Ablynx N.V. |
Immunoglobulin constructs
|
ES2614284T3
(es)
|
2007-11-30 |
2017-05-30 |
Glaxo Group Limited |
Construcciones de unión a antígenos
|
PL2690101T3
(pl)
|
2007-12-19 |
2015-12-31 |
Genentech Inc |
5-anilinoimidazopirydyny i sposoby zastosowania
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
EP2235064B1
(en)
|
2008-01-07 |
2015-11-25 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
WO2009102465A2
(en)
|
2008-02-13 |
2009-08-20 |
President And Fellows Of Harvard College |
Continuous cell programming devices
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
PE20091628A1
(es)
|
2008-03-19 |
2009-11-19 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
|
CN108586463A
(zh)
|
2008-05-21 |
2018-09-28 |
因西特控股公司 |
2-氟-N-甲基-4-[7-(喹啉-6-基甲基)咪唑并[1,2-b][1,2,4]三嗪-2-基]苯甲酰胺的盐及与其相关的制备方法
|
ES2554513T3
(es)
|
2008-05-23 |
2015-12-21 |
Novartis Ag |
Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
|
UY31929A
(es)
|
2008-06-25 |
2010-01-05 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
WO2010003118A1
(en)
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
CN102124009B
(zh)
|
2008-07-08 |
2014-07-23 |
因特利凯公司 |
激酶抑制剂及其使用方法
|
HUE025778T2
(en)
|
2008-07-17 |
2016-05-30 |
Novartis Ag |
Preparations and methods for the use of therapeutic antibodies
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
KR101353857B1
(ko)
|
2008-08-22 |
2014-01-21 |
노파르티스 아게 |
Cdk 억제제로서 피롤로피리미딘 화합물
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
EP2328919A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
CN102203079B
(zh)
|
2008-09-02 |
2014-12-10 |
诺华股份有限公司 |
作为激酶抑制剂的吡啶甲酰胺衍生物
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
EP2370076B1
(en)
|
2008-11-28 |
2017-01-04 |
Novartis AG |
Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
|
HUE034832T2
(hu)
|
2008-12-09 |
2021-12-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
|
US8591881B2
(en)
|
2009-02-05 |
2013-11-26 |
Mount Sinai School Of Medicine |
Chimeric Newcastle disease viruses and uses thereof
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
WO2010125571A1
(en)
|
2009-04-30 |
2010-11-04 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anti ceacam1 antibodies and methods of using same
|
JO2892B1
(en)
|
2009-06-26 |
2015-09-15 |
نوفارتيس ايه جي |
CYP inhibitors 17
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
ANTI-GITRANT ANTIBODIES
|
IT1395574B1
(it)
|
2009-09-14 |
2012-10-16 |
Guala Dispensing Spa |
Dispositivo di erogazione
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
AU2010343057B2
(en)
|
2009-12-29 |
2017-02-23 |
Aptevo Research And Development Llc |
Heterodimer binding proteins and uses thereof
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
KR101930964B1
(ko)
|
2010-04-20 |
2018-12-19 |
젠맵 에이/에스 |
이종이량체 항체 fc-함유 단백질 및 그의 생산 방법
|
EP3363499A1
(en)
|
2010-06-11 |
2018-08-22 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-tim-3 antibody
|
CA2804550C
(en)
|
2010-07-09 |
2021-01-05 |
Bionovion Holding B.V. |
Agonistic antibody to cd27
|
JP6057896B2
(ja)
|
2010-08-20 |
2017-01-11 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)に対する抗体
|
MY171312A
(en)
|
2010-08-23 |
2019-10-08 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
AU2011305476B2
(en)
|
2010-09-21 |
2016-12-01 |
Altor Bioscience Corporation |
Multimeric IL-15 soluble fusion molecules and methods of making and using same
|
JP6104806B2
(ja)
|
2010-10-06 |
2017-03-29 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
|
WO2012149358A1
(en)
|
2011-04-28 |
2012-11-01 |
President And Fellows Of Harvard College |
Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
|
JP6062426B2
(ja)
|
2011-06-03 |
2017-01-18 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
インサイチュー抗原生成癌ワクチン
|
KR102577578B1
(ko)
|
2011-06-03 |
2023-09-11 |
조마 테크놀로지 리미티드 |
Tgf-베타에 특이적인 항체
|
AU2012273182A1
(en)
|
2011-06-21 |
2014-01-16 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
CN103842030B
(zh)
|
2011-08-01 |
2018-07-31 |
霍夫曼-拉罗奇有限公司 |
使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
EP3674320A3
(en)
|
2011-10-27 |
2020-08-12 |
Genmab A/S |
Production of heterodimeric proteins
|
JP6138813B2
(ja)
|
2011-11-28 |
2017-05-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗pd−l1抗体及びその使用
|
EP2785743B1
(en)
|
2011-12-01 |
2019-08-14 |
The Brigham and Women's Hospital, Inc. |
Anti-ceacam1 recombinant antibodies for cancer therapy
|
AU2013207687B2
(en)
|
2012-01-13 |
2017-11-30 |
Dana-Farber Cancer Institute, Inc. |
Controlled delivery of TLR agonists in structural polymeric devices
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
AU2013240340B2
(en)
|
2012-03-29 |
2016-11-10 |
Advanced Cancer Therapeutics, Llc |
PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic
|
LT2838515T
(lt)
|
2012-04-16 |
2020-03-10 |
President And Fellows Of Harvard College |
Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
|
WO2013158292A1
(en)
|
2012-04-17 |
2013-10-24 |
University Of Washington Through Its Center For Commercialization |
Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
|
PL2900637T3
(pl)
|
2012-05-15 |
2018-01-31 |
Novartis Ag |
Pirymidyna podstawiona tiazolem lub imidazolem, amidowe pochodne pirazyny i pirydyny i powiązane związki takie jak inhibitory abl1, abl2 i bcr-abl1 do leczenia nowotworu, specyficznych infekcji wirusowych i specyficznych zaburzeń cns
|
BR112014027181A2
(pt)
|
2012-05-15 |
2017-06-27 |
Novartis Ag |
derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
|
US9340537B2
(en)
|
2012-05-15 |
2016-05-17 |
Novatis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
TR201807023T4
(tr)
|
2012-05-15 |
2018-06-21 |
Novartis Ag |
Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri.
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th17 세포 전환용 에피토프 및 이의 용도
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
US10513540B2
(en)
|
2012-07-31 |
2019-12-24 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
MX365527B
(es)
|
2012-10-24 |
2019-06-06 |
Us Health |
Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r.
|
RU2015121367A
(ru)
|
2012-11-08 |
2017-01-10 |
Новартис Аг |
Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
|
BR112015012197A8
(pt)
|
2012-11-28 |
2019-10-01 |
Novartis Ag |
usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
|
EA031537B1
(ru)
|
2013-02-08 |
2019-01-31 |
Новартис Аг |
Антитела против il-17a и их применение для лечения аутоиммунных и воспалительных нарушений
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
KR20150131224A
(ko)
|
2013-03-14 |
2015-11-24 |
노파르티스 아게 |
돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
AU2014241843B2
(en)
|
2013-03-14 |
2019-05-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
CN105188373B
(zh)
|
2013-05-18 |
2017-09-22 |
艾杜罗生物科技公司 |
抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
|
MY175308A
(en)
|
2013-05-18 |
2020-06-18 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
ES2749744T3
(es)
|
2013-09-11 |
2020-03-23 |
Medimmune Ltd |
Anticuerpos anti-B7-H1 para tratar tumores
|
MX355480B
(es)
|
2013-11-01 |
2018-04-19 |
Novartis Ag |
Amino-heteroaril-benzamidas como inhibidores de cinasa.
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN106103484B
(zh)
*
|
2014-03-14 |
2021-08-20 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|